Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020

This study provides a retrospective analysis of the recommendations of the French National Health Authority on the reimbursement and pricing of innovative drugs. The analysis includes drugs subjected to both economic and clinical evaluations in France from 2014 to 2020. Ordered logistic and quantile...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2021-12, Vol.24 (12), p.1784-1791
Hauptverfasser: Kergall, Pauline, Autin, Erwan, Guillon, Marlène, Clément, Valérie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1791
container_issue 12
container_start_page 1784
container_title Value in health
container_volume 24
creator Kergall, Pauline
Autin, Erwan
Guillon, Marlène
Clément, Valérie
description This study provides a retrospective analysis of the recommendations of the French National Health Authority on the reimbursement and pricing of innovative drugs. The analysis includes drugs subjected to both economic and clinical evaluations in France from 2014 to 2020. Ordered logistic and quantile regressions are used to estimate the factors associated with the clinical value (SMR), the clinical added value (ASMR), and the incremental cost-utility ratio (ICUR) of innovative drugs. All variables used in the regression analyses are extracted from the Clinical and Economic Opinions for the 146 observations. Regression analyses indicate that 2 of the 5 official criteria, the efficacy-adverse events balance of the drug and its function, are significantly associated with the SMR rating. The ASMR is positively associated with the disease severity, the quality-adjusted life-year (QALY) gain provided by the drug, and the validation of the ICUR in the Economic Opinion. At the first quartile of the ICUR distribution (approximately €50 000/QALY), higher ICUR levels are observed for drugs with a smaller target population and for drugs claimed as more innovative. Higher ICUR levels are also observed for pediatric drugs and for drugs with no therapeutic alternative at the third quartile of the distribution (approximately €240 000/QALY). Not all official criteria of the SMR are associated with actual ratings obtained. Regarding the ASMR, the results support the idea of a convergence between the 2 independent clinical and economic appraisal processes. Finally, the factors influencing the ICUR level vary across the distribution of ICUR. •The analysis of the recommendations of the French National Health Authority for innovative drugs entering the market between 2014 and 2020 shows that not all official criteria are considered in the reimbursement and pricing decisions, which questions the transparency and predictability of the French health technology assessment process.•Although the clinical and economic assessments are independent in the French health technology assessment process, results show consistency between the clinical and economic evaluations regarding the added value of new drugs.•We document the incremental cost-utility ratio (ICUR) levels of innovative drugs in France, and we find that drug and disease characteristics associated with the ICURs vary across the ICUR distribution.
doi_str_mv 10.1016/j.jval.2021.06.013
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03515591v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1098301521016429</els_id><sourcerecordid>2618164095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-72360112c6b8368f49767473d7f2ade6589c116afcc674ff9c374789efe64fb93</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxiMEoqXwAhyQJS5wSPC_OAniEi0tW2kFCMHZ8jrjjaMkXuwk0j4E71ynW3rgwGmsz7_5NDNfkrwmOCOYiA9d1i2qzyimJMMiw4Q9SS5JTnnKC8aexjeuypRhkl8kL0LoMMaC0fx5csF4yUpaiMvkz8Yt4NUBkBob9N1bbccD-gHaDQOMjZqsGwNyBk0toBsPo27R13tV9WgLqp9aVM9T67ydTsg4j27H0S2RWAB99vMhfER19Ju8C0fQ93Ide0_BhujnBkQx4WhysVL8MnlmVB_g1UO9Sn7dXP_cbNPdty-3m3qXai7olBaUCUwI1WJfMlEaXhWiiDs3haGqAZGXlSZEKKN11I2pNIvfZQUGBDf7il0l78--rerl0dtB-ZN0ysptvZOrhllO8rwiC4nsuzN79O73DGGSgw0a-l6N4OYgqcCc52XORETf_oN2bvZx25UiJREcV3mk6JnS8SbBg3mcgGC5Bis7uQYr12AlFjIGG5vePFjP-wGax5a_SUbg0xmAeLfFgpdB2xgXNNbHu8vG2f_53wGUwLHz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618164095</pqid></control><display><type>article</type><title>Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kergall, Pauline ; Autin, Erwan ; Guillon, Marlène ; Clément, Valérie</creator><creatorcontrib>Kergall, Pauline ; Autin, Erwan ; Guillon, Marlène ; Clément, Valérie</creatorcontrib><description>This study provides a retrospective analysis of the recommendations of the French National Health Authority on the reimbursement and pricing of innovative drugs. The analysis includes drugs subjected to both economic and clinical evaluations in France from 2014 to 2020. Ordered logistic and quantile regressions are used to estimate the factors associated with the clinical value (SMR), the clinical added value (ASMR), and the incremental cost-utility ratio (ICUR) of innovative drugs. All variables used in the regression analyses are extracted from the Clinical and Economic Opinions for the 146 observations. Regression analyses indicate that 2 of the 5 official criteria, the efficacy-adverse events balance of the drug and its function, are significantly associated with the SMR rating. The ASMR is positively associated with the disease severity, the quality-adjusted life-year (QALY) gain provided by the drug, and the validation of the ICUR in the Economic Opinion. At the first quartile of the ICUR distribution (approximately €50 000/QALY), higher ICUR levels are observed for drugs with a smaller target population and for drugs claimed as more innovative. Higher ICUR levels are also observed for pediatric drugs and for drugs with no therapeutic alternative at the third quartile of the distribution (approximately €240 000/QALY). Not all official criteria of the SMR are associated with actual ratings obtained. Regarding the ASMR, the results support the idea of a convergence between the 2 independent clinical and economic appraisal processes. Finally, the factors influencing the ICUR level vary across the distribution of ICUR. •The analysis of the recommendations of the French National Health Authority for innovative drugs entering the market between 2014 and 2020 shows that not all official criteria are considered in the reimbursement and pricing decisions, which questions the transparency and predictability of the French health technology assessment process.•Although the clinical and economic assessments are independent in the French health technology assessment process, results show consistency between the clinical and economic evaluations regarding the added value of new drugs.•We document the incremental cost-utility ratio (ICUR) levels of innovative drugs in France, and we find that drug and disease characteristics associated with the ICURs vary across the ICUR distribution.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2021.06.013</identifier><identifier>PMID: 34838276</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Advisory Committees ; Analysis ; Authority ; clinical added value ; Clinical assessment ; clinical benefit ; Clinical trials ; Commerce ; Convergence ; Cost analysis ; Critical incidents ; drug pricing ; Economic appraisal ; economic evaluation ; Economics and Finance ; Efficacy ; France ; health technology assessment ; Humanities and Social Sciences ; incremental cost-utility ratio ; Monte Carlo simulation ; Pediatrics ; Pharmaceutical Preparations - economics ; Prescription drugs ; Quality adjusted life years ; Regression Analysis ; Reimbursement ; Retrospective Studies ; Value</subject><ispartof>Value in health, 2021-12, Vol.24 (12), p.1784-1791</ispartof><rights>2021 ISPOR–The Professional Society for Health Economics and Outcomes Research</rights><rights>Copyright © 2021 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Dec 2021</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-72360112c6b8368f49767473d7f2ade6589c116afcc674ff9c374789efe64fb93</citedby><cites>FETCH-LOGICAL-c462t-72360112c6b8368f49767473d7f2ade6589c116afcc674ff9c374789efe64fb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jval.2021.06.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,30999,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34838276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-03515591$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kergall, Pauline</creatorcontrib><creatorcontrib>Autin, Erwan</creatorcontrib><creatorcontrib>Guillon, Marlène</creatorcontrib><creatorcontrib>Clément, Valérie</creatorcontrib><title>Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020</title><title>Value in health</title><addtitle>Value Health</addtitle><description>This study provides a retrospective analysis of the recommendations of the French National Health Authority on the reimbursement and pricing of innovative drugs. The analysis includes drugs subjected to both economic and clinical evaluations in France from 2014 to 2020. Ordered logistic and quantile regressions are used to estimate the factors associated with the clinical value (SMR), the clinical added value (ASMR), and the incremental cost-utility ratio (ICUR) of innovative drugs. All variables used in the regression analyses are extracted from the Clinical and Economic Opinions for the 146 observations. Regression analyses indicate that 2 of the 5 official criteria, the efficacy-adverse events balance of the drug and its function, are significantly associated with the SMR rating. The ASMR is positively associated with the disease severity, the quality-adjusted life-year (QALY) gain provided by the drug, and the validation of the ICUR in the Economic Opinion. At the first quartile of the ICUR distribution (approximately €50 000/QALY), higher ICUR levels are observed for drugs with a smaller target population and for drugs claimed as more innovative. Higher ICUR levels are also observed for pediatric drugs and for drugs with no therapeutic alternative at the third quartile of the distribution (approximately €240 000/QALY). Not all official criteria of the SMR are associated with actual ratings obtained. Regarding the ASMR, the results support the idea of a convergence between the 2 independent clinical and economic appraisal processes. Finally, the factors influencing the ICUR level vary across the distribution of ICUR. •The analysis of the recommendations of the French National Health Authority for innovative drugs entering the market between 2014 and 2020 shows that not all official criteria are considered in the reimbursement and pricing decisions, which questions the transparency and predictability of the French health technology assessment process.•Although the clinical and economic assessments are independent in the French health technology assessment process, results show consistency between the clinical and economic evaluations regarding the added value of new drugs.•We document the incremental cost-utility ratio (ICUR) levels of innovative drugs in France, and we find that drug and disease characteristics associated with the ICURs vary across the ICUR distribution.</description><subject>Advisory Committees</subject><subject>Analysis</subject><subject>Authority</subject><subject>clinical added value</subject><subject>Clinical assessment</subject><subject>clinical benefit</subject><subject>Clinical trials</subject><subject>Commerce</subject><subject>Convergence</subject><subject>Cost analysis</subject><subject>Critical incidents</subject><subject>drug pricing</subject><subject>Economic appraisal</subject><subject>economic evaluation</subject><subject>Economics and Finance</subject><subject>Efficacy</subject><subject>France</subject><subject>health technology assessment</subject><subject>Humanities and Social Sciences</subject><subject>incremental cost-utility ratio</subject><subject>Monte Carlo simulation</subject><subject>Pediatrics</subject><subject>Pharmaceutical Preparations - economics</subject><subject>Prescription drugs</subject><subject>Quality adjusted life years</subject><subject>Regression Analysis</subject><subject>Reimbursement</subject><subject>Retrospective Studies</subject><subject>Value</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNp9kc9u1DAQxiMEoqXwAhyQJS5wSPC_OAniEi0tW2kFCMHZ8jrjjaMkXuwk0j4E71ynW3rgwGmsz7_5NDNfkrwmOCOYiA9d1i2qzyimJMMiw4Q9SS5JTnnKC8aexjeuypRhkl8kL0LoMMaC0fx5csF4yUpaiMvkz8Yt4NUBkBob9N1bbccD-gHaDQOMjZqsGwNyBk0toBsPo27R13tV9WgLqp9aVM9T67ydTsg4j27H0S2RWAB99vMhfER19Ju8C0fQ93Ide0_BhujnBkQx4WhysVL8MnlmVB_g1UO9Sn7dXP_cbNPdty-3m3qXai7olBaUCUwI1WJfMlEaXhWiiDs3haGqAZGXlSZEKKN11I2pNIvfZQUGBDf7il0l78--rerl0dtB-ZN0ysptvZOrhllO8rwiC4nsuzN79O73DGGSgw0a-l6N4OYgqcCc52XORETf_oN2bvZx25UiJREcV3mk6JnS8SbBg3mcgGC5Bis7uQYr12AlFjIGG5vePFjP-wGax5a_SUbg0xmAeLfFgpdB2xgXNNbHu8vG2f_53wGUwLHz</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Kergall, Pauline</creator><creator>Autin, Erwan</creator><creator>Guillon, Marlène</creator><creator>Clément, Valérie</creator><general>Elsevier Inc</general><general>Elsevier Science Ltd</general><general>Elsevier [1988-....]</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7X8</scope><scope>1XC</scope><scope>BXJBU</scope><scope>IHQJB</scope><scope>VOOES</scope></search><sort><creationdate>20211201</creationdate><title>Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020</title><author>Kergall, Pauline ; Autin, Erwan ; Guillon, Marlène ; Clément, Valérie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-72360112c6b8368f49767473d7f2ade6589c116afcc674ff9c374789efe64fb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Advisory Committees</topic><topic>Analysis</topic><topic>Authority</topic><topic>clinical added value</topic><topic>Clinical assessment</topic><topic>clinical benefit</topic><topic>Clinical trials</topic><topic>Commerce</topic><topic>Convergence</topic><topic>Cost analysis</topic><topic>Critical incidents</topic><topic>drug pricing</topic><topic>Economic appraisal</topic><topic>economic evaluation</topic><topic>Economics and Finance</topic><topic>Efficacy</topic><topic>France</topic><topic>health technology assessment</topic><topic>Humanities and Social Sciences</topic><topic>incremental cost-utility ratio</topic><topic>Monte Carlo simulation</topic><topic>Pediatrics</topic><topic>Pharmaceutical Preparations - economics</topic><topic>Prescription drugs</topic><topic>Quality adjusted life years</topic><topic>Regression Analysis</topic><topic>Reimbursement</topic><topic>Retrospective Studies</topic><topic>Value</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kergall, Pauline</creatorcontrib><creatorcontrib>Autin, Erwan</creatorcontrib><creatorcontrib>Guillon, Marlène</creatorcontrib><creatorcontrib>Clément, Valérie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société (Open Access)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kergall, Pauline</au><au>Autin, Erwan</au><au>Guillon, Marlène</au><au>Clément, Valérie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>24</volume><issue>12</issue><spage>1784</spage><epage>1791</epage><pages>1784-1791</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>This study provides a retrospective analysis of the recommendations of the French National Health Authority on the reimbursement and pricing of innovative drugs. The analysis includes drugs subjected to both economic and clinical evaluations in France from 2014 to 2020. Ordered logistic and quantile regressions are used to estimate the factors associated with the clinical value (SMR), the clinical added value (ASMR), and the incremental cost-utility ratio (ICUR) of innovative drugs. All variables used in the regression analyses are extracted from the Clinical and Economic Opinions for the 146 observations. Regression analyses indicate that 2 of the 5 official criteria, the efficacy-adverse events balance of the drug and its function, are significantly associated with the SMR rating. The ASMR is positively associated with the disease severity, the quality-adjusted life-year (QALY) gain provided by the drug, and the validation of the ICUR in the Economic Opinion. At the first quartile of the ICUR distribution (approximately €50 000/QALY), higher ICUR levels are observed for drugs with a smaller target population and for drugs claimed as more innovative. Higher ICUR levels are also observed for pediatric drugs and for drugs with no therapeutic alternative at the third quartile of the distribution (approximately €240 000/QALY). Not all official criteria of the SMR are associated with actual ratings obtained. Regarding the ASMR, the results support the idea of a convergence between the 2 independent clinical and economic appraisal processes. Finally, the factors influencing the ICUR level vary across the distribution of ICUR. •The analysis of the recommendations of the French National Health Authority for innovative drugs entering the market between 2014 and 2020 shows that not all official criteria are considered in the reimbursement and pricing decisions, which questions the transparency and predictability of the French health technology assessment process.•Although the clinical and economic assessments are independent in the French health technology assessment process, results show consistency between the clinical and economic evaluations regarding the added value of new drugs.•We document the incremental cost-utility ratio (ICUR) levels of innovative drugs in France, and we find that drug and disease characteristics associated with the ICURs vary across the ICUR distribution.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34838276</pmid><doi>10.1016/j.jval.2021.06.013</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2021-12, Vol.24 (12), p.1784-1791
issn 1098-3015
1524-4733
language eng
recordid cdi_hal_primary_oai_HAL_hal_03515591v1
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Applied Social Sciences Index & Abstracts (ASSIA); Access via ScienceDirect (Elsevier)
subjects Advisory Committees
Analysis
Authority
clinical added value
Clinical assessment
clinical benefit
Clinical trials
Commerce
Convergence
Cost analysis
Critical incidents
drug pricing
Economic appraisal
economic evaluation
Economics and Finance
Efficacy
France
health technology assessment
Humanities and Social Sciences
incremental cost-utility ratio
Monte Carlo simulation
Pediatrics
Pharmaceutical Preparations - economics
Prescription drugs
Quality adjusted life years
Regression Analysis
Reimbursement
Retrospective Studies
Value
title Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A36%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Coverage%20and%20Pricing%20Recommendations%20of%20the%20French%20National%20Health%20Authority%20for%20Innovative%20Drugs:%20A%20Retrospective%20Analysis%20From%202014%20to%202020&rft.jtitle=Value%20in%20health&rft.au=Kergall,%20Pauline&rft.date=2021-12-01&rft.volume=24&rft.issue=12&rft.spage=1784&rft.epage=1791&rft.pages=1784-1791&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2021.06.013&rft_dat=%3Cproquest_hal_p%3E2618164095%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618164095&rft_id=info:pmid/34838276&rft_els_id=S1098301521016429&rfr_iscdi=true